AsymBio Secures US$184 Million Capital Injection to Support Long-Term Growth

AsymBio Secures US$184 Million Capital Injection to Support Long-Term Growth

SHANGHAI, Aug. 4, 2026 /PRNewswire/ -- AsymBio, a biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group (stock codes: 002821.SZ / 6821.HK), today announced a total capital injection of RMB...

menu
menu